Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02987543 · ClinicalTrials.gov registry record · Phase 3
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 387
- Enrollment target
NCT02987543 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 387 participants.
The verdict
NCT02987543, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 387 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
Interventions
- DRUG enzalutamide
- DRUG abiraterone acetate
- DRUG olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02987543
The ClinicalTrials.gov registry entry for NCT02987543 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which enzalutamide is the first listed.
NCT02987543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02987543 about?
NCT02987543 is a clinical study titled "Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)". The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
What is the current status of trial NCT02987543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 387 participants. The study started on 2017-02-06. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT02987543?
The interventions under investigation include: enzalutamide (DRUG), abiraterone acetate (DRUG), olaparib (DRUG).
Who is sponsoring clinical trial NCT02987543?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.